81 FR 1955 - Patient and Medical Professional Perspectives on the Return of Genetic Test Results and Interpretations; Public Workshop; Request for Comments
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration Federal Register Volume 81, Issue 9 (January 14, 2016)
Food and Drug Administration
Federal Register Volume 81, Issue 9 (January 14, 2016)
| Page Range | 1955-1957 | |
| FR Document | 2016-00540 |
[Federal Register Volume 81, Number 9 (Thursday, January 14, 2016)] [Notices] [Pages 1955-1957] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2016-00540] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2015-N-4809] Patient and Medical Professional Perspectives on the Return of Genetic Test Results and Interpretations; Public Workshop; Request for Comments AGENCY: Food and Drug Administration, HHS. ACTION: Notice of public workshop; request for comments. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration (FDA) is announcing the following public workshop entitled ``Patient and Medical Professional Perspectives on the Return of Genetic Test Results.'' The purpose of this public workshop is to understand patient and provider perspectives on receiving potentially medically relevant genetic test results. The topic(s) to be discussed will focus on better defining the specific information patients and providers prefer to receive, with an emphasis on the type(s) and amount of evidence available to interpret the results for medical purposes, how those results should be returned, and what information is needed to understand the results in the event that they could effectively aid in medical decision making. DATES: The public workshop will be held on March 2, 2016, from 8 a.m. to 4 p.m. Submit either electronic or written comments on the public workshop by March 31, 2016. ADDRESSES: The public workshop will be held at FDA's White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD 20993. Entrance for the public meeting participants (non-FDA employees) is through Building 1, where routine security check procedures will be performed. For parking and security information, please refer to http://www.fda.gov/AboutFDA/WorkingatFDA/BuildingsandFacilities/WhiteOakCampusInformation/ucm241740.htm. You may submit comments as follows: Electronic Submissions Submit electronic comments in the following way:Federal eRulemaking Portal: http://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to http://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on http://www.regulations.gov. If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ``Written/Paper Submissions'' and ``Instructions''). Written/Paper Submissions Submit written/paper submissions as follows: Mail/Hand delivery/Courier (for written/paper submissions): Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. For written/paper comments submitted to the Division of Dockets Management, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ``Instructions.'' Instructions: All submissions received must include the Docket No. FDA-2015-N-4809 for ``Patient and Medical Professional Perspectives on the Return of Genetic Test Results; Public Workshop; Request for Comments.'' Received comments will be placed in the docket and, except for those submitted as ``Confidential Submissions,'' publicly viewable at http://www.regulations.gov or at the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. Confidential Submissions--To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION''. The Agency will review this copy, including [[Page 1956]] the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on http://www.regulations.gov. Submit both copies to the Division of Dockets Management. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ``confidential.'' Any information marked as ``confidential'' will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: http://www.fda.gov/regulatoryinformation/dockets/default.htm. Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to http://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the ``Search'' box and follow the prompts and/or go to the Division of Dockets Management, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. FOR FURTHER INFORMATION CONTACT: Cara Tenenbaum, Center for Devices and Radiological Health, Food and Drug Administration, Bldg. 66, Rm. 5563, 10903 New Hampshire Ave., Silver Spring, MD 20993, 301-796-8456, [email protected]. SUPPLEMENTARY INFORMATION: I. Background In his State of the Union address on January 20, 2015, President Obama launched the Precision Medicine Initiative (PMI),\1\ in order to empower health care providers to tailor treatment and prevention strategies to an individual's unique characteristics. This may include analysis of genetic information, including information gathered through Next Generation Sequencing (NGS). As part of PMI, FDA is considering new approaches in its regulation of NGS. FDA is interested in promoting innovation while ensuring that patients have access to cutting edge technologies that are accurate and provide meaningful information to inform their health care decisions. --------------------------------------------------------------------------- \1\ The Precision Medicine Initiative found on the White House's Web site at: https://www.whitehouse.gov/precision-medicine. --------------------------------------------------------------------------- NGS produces significant amounts of information, including some that may be difficult for patients and health care professionals to interpret with presently available scientific knowledge. In some cases, the evidence for association of many genetic variants with particular diseases is limited because of the rarity of the variant or because it partially contributes to a disease in combination with other factors. In other cases, the evidence may be contradictory or not be available currently, but may be clearer in the future. Additionally, some findings may be unexpected or incidental to what a physician is looking for. FDA seeks to learn, when results are generated in a CLIA-compliant laboratory, which results are of importance to patients and providers, how those results should be returned, and how much and what types of evidence supporting interpretation of those results is necessary. Thus, FDA is seeking public input from patients and health care professionals to inform its approach regarding the return of results of genetic tests. II. Topics for Discussion at the Public Workshop In response to President Obama's PMI, the public workshop will consider the different uses of genetic testing. For example, tests that determine the risk of developing a condition, tests that diagnose hereditary genetic disorders, and tests that can guide treatment or therapeutic interventions. Additionally, the workshop and invited speakers will cover various topics, including which results (e.g., variants or mutations) and interpretations are useful to patients when undergoing genetic testing; what types of results patients would want to receive when there is no medical action that can be taken; how best can results of genetic test be presented; patients' preference in receiving results that are supported by limited or conflicting evidence and how best such results should be presented; how information can be best presented to ease integration into clinical care and health care provider workflow; what providers want to know about results that are supported by limited or conflicting evidence; what information should be included in test reports and how it should be presented; and what specific information providers can do without. FDA will present case studies as a starting point for discussion, which will be available on the meeting Web page in advance of the public meeting. Furthermore, the following will be considered in the context of different uses of genetic testing: Health literacy/numeracy of patients; genetics/genomics literacy of health care practitioners; the personal utility of knowing about the presence of a mutation or variant whether it is actionable or not; that a mutation or variant may have limited evidence at the time the test is initially run but evidence may be gathered that changes the interpretation of the mutation or variant; privacy concerns; demographic information and subpopulations; undiagnosed patients; and underserved populations. Registration: Registration is free and available on a first-come, first-served basis. Persons interested in attending this public workshop must register online by February 24, 2016, 4 p.m. Early registration is recommended because space is limited and, therefore, FDA may limit the number of participants from each organization. If time and space permits, onsite registration on the day of the public workshop will be provided beginning at 8 a.m. If you need special accommodations due to a disability, please contact Susan Monahan, email: [email protected], phone: 301- 796-5661, no later than February 20, 2016. To register for the public workshop, please visit FDA's Medical Devices News & Events--Workshops & Conferences calendar at http://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/default.htm. (Select this meeting/public workshop from the posted events list.) Please provide complete contact information for each attendee, including name, title, affiliation, email, and telephone number. Those without Internet access should contact Susan Monahan to register (see contact for special accommodations). Registrants will receive confirmation after they have been accepted. You will be notified if you are on a waiting list. Streaming Webcast of the Public Workshop: This public workshop will also be Webcast. If you have never attended a Connect Pro event before, test your connection at https://collaboration.fda.gov/common/help/en/support/meeting_test.htm. To get a quick overview of the Connect Pro program, visit http://www.adobe.com/go/connectpro_overview. FDA has verified the Web site addresses in this document, as of the date this document publishes in the Federal Register, but Web sites are subject to change over time. Requests for Oral Presentations: This public workshop includes public comment and topic-focused sessions. During online registration you may indicate if you wish to present during a public comment session. FDA has [[Page 1957]] included general topics for discussion in this document. If you do request to present public comments, please list which topics you wish to address. FDA will do its best to accommodate requests to make public comment. Following the close of registration, FDA will determine the amount of time allotted to each presenter and the approximate time each oral presentation is to begin, and will select and notify participants by February 24, 2016. All requests to make oral presentations must be received by the close of registration on February 24, 2016, at 4 p.m. If selected for presentation, any presentation materials must be emailed to Cara Tenenbaum (see FURTHER INFORMATION CONTACT) no later than February 26, 2016. No commercial promotional material will be permitted to be presented or distributed at the public workshop. Transcripts: Please be advised that as soon as a transcript is available, it will be accessible at http://www.regulations.gov. It may be viewed at the Division of Dockets Management (see ADDRESSES). A transcript will also be available in either hardcopy or on CD-ROM, after submission of a Freedom of Information request. The Freedom of Information office address is available on the Agency's Web site at http://www.fda.gov. A link to the transcripts will also be available approximately 45 days after the public workshop on the Internet at http://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/default.htm. (Select this public workshop from the posted events list.) Dated: January 7, 2016. Leslie Kux, Associate Commissioner for Policy. [FR Doc. 2016-00540 Filed 1-13-16; 8:45 am] BILLING CODE 4164-01-P
![Federal Register / Vol. 81, No. 9 / Thursday, January 14, 2016 / Notices 1955
ANNUAL BURDEN ESTIMATES
Number of Average
Number of Total burden
Instrument responses per burden hours
respondents hours
respondent per response
Tribal PREP Plan ............................................................................................. 10 1 40 400
Estimated Total Annual Burden ACTION: Notice of public workshop; third party may not wish to be posted,
Hours: 400. request for comments. such as medical information, your or
In compliance with the requirements anyone else’s Social Security number, or
of Section 3506(c)(2)(A) of the SUMMARY: The Food and Drug confidential business information, such
Paperwork Reduction Act of 1995, the Administration (FDA) is announcing the as a manufacturing process. Please note
Administration for Children and following public workshop entitled that if you include your name, contact
Families is soliciting public comment ‘‘Patient and Medical Professional information, or other information that
on the specific aspects of the Perspectives on the Return of Genetic identifies you in the body of your
information collection described above. Test Results.’’ The purpose of this comments, that information will be
Copies of the proposed collection of public workshop is to understand posted on http://www.regulations.gov.
information can be obtained and patient and provider perspectives on • If you want to submit a comment
comments may be forwarded by writing receiving potentially medically relevant with confidential information that you
to the Administration for Children and genetic test results. The topic(s) to be do not wish to be made available to the
Families, Office of Administration, discussed will focus on better defining public, submit the comment as a
Office of Information Services, 370 the specific information patients and written/paper submission and in the
L’Enfant Promenade SW., Washington, providers prefer to receive, with an manner detailed (see ‘‘Written/Paper
DC 20447, Attn: ACF Reports Clearance emphasis on the type(s) and amount of Submissions’’ and ‘‘Instructions’’).
Officer. Email address: infocollection@ evidence available to interpret the
acf.hhs.gov. All requests should be results for medical purposes, how those Written/Paper Submissions
identified by the title of the information results should be returned, and what Submit written/paper submissions as
collection. information is needed to understand the follows:
The Department specifically requests results in the event that they could • Mail/Hand delivery/Courier (for
comments on: (a) whether the proposed effectively aid in medical decision written/paper submissions): Division of
collection of information is necessary making. Dockets Management (HFA–305), Food
for the proper performance of the DATES: The public workshop will be and Drug Administration, 5630 Fishers
functions of the agency, including held on March 2, 2016, from 8 a.m. to Lane, Rm. 1061, Rockville, MD 20852.
whether the information shall have 4 p.m. Submit either electronic or • For written/paper comments
practical utility; (b) the accuracy of the written comments on the public submitted to the Division of Dockets
agency’s estimate of the burden of the workshop by March 31, 2016. Management, FDA will post your
proposed collection of information; (c) ADDRESSES: The public workshop will comment, as well as any attachments,
the quality, utility, and clarity of the be held at FDA’s White Oak Campus, except for information submitted,
information to be collected; and (d) 10903 New Hampshire Ave., Bldg. 31 marked and identified, as confidential,
ways to minimize the burden of the Conference Center, the Great Room (Rm. if submitted as detailed in
collection of information on 1503), Silver Spring, MD 20993. ‘‘Instructions.’’
respondents, including through the use Entrance for the public meeting Instructions: All submissions received
of automated collection techniques or participants (non-FDA employees) is must include the Docket No. FDA–
other forms of information technology. through Building 1, where routine 2015–N–4809 for ‘‘Patient and Medical
Consideration will be given to security check procedures will be Professional Perspectives on the Return
comments and suggestions submitted performed. For parking and security of Genetic Test Results; Public
within 60 days of this publication. information, please refer to http://www. Workshop; Request for Comments.’’
Robert Sargis, fda.gov/AboutFDA/WorkingatFDA/ Received comments will be placed in
Reports Clearance Officer. BuildingsandFacilities/WhiteOak the docket and, except for those
CampusInformation/ucm241740.htm. submitted as ‘‘Confidential
[FR Doc. 2016–00595 Filed 1–13–16; 8:45 am]
You may submit comments as Submissions,’’ publicly viewable at
BILLING CODE 4184–01–P
follows: http://www.regulations.gov or at the
Division of Dockets Management
Electronic Submissions between 9 a.m. and 4 p.m., Monday
DEPARTMENT OF HEALTH AND
HUMAN SERVICES Submit electronic comments in the through Friday.
following way: • Confidential Submissions—To
Food and Drug Administration • Federal eRulemaking Portal: http:// submit a comment with confidential
www.regulations.gov. Follow the information that you do not wish to be
[Docket No. FDA–2015–N–4809] instructions for submitting comments. made publicly available, submit your
mstockstill on DSK4VPTVN1PROD with NOTICES
Comments submitted electronically, comments only as a written/paper
Patient and Medical Professional
including attachments, to http:// submission. You should submit two
Perspectives on the Return of Genetic
www.regulations.gov will be posted to copies total. One copy will include the
Test Results and Interpretations;
the docket unchanged. Because your information you claim to be confidential
Public Workshop; Request for
comment will be made public, you are with a heading or cover note that states
Comments
solely responsible for ensuring that your ‘‘THIS DOCUMENT CONTAINS
AGENCY: Food and Drug Administration, comment does not include any CONFIDENTIAL INFORMATION’’. The
HHS. confidential information that you or a Agency will review this copy, including
VerDate Sep<11>2014 18:58 Jan 13, 2016 Jkt 238001 PO 00000 Frm 00019 Fmt 4703 Sfmt 4703 E:\FR\FM\14JAN1.SGM 14JAN1](https://thefederalregister.org/doc/81_FR_1964/page/1.svg)
![Federal Register / Vol. 81, No. 9 / Thursday, January 14, 2016 / Notices 1957
included general topics for discussion announcing the availability of a written/paper submission and in the
in this document. If you do request to document entitled ‘‘Revised Preventive manner detailed (see ‘‘Written/Paper
present public comments, please list Measures to Reduce the Possible Risk of Submissions’’ and ‘‘Instructions’’).
which topics you wish to address. FDA Transmission of Creutzfeldt-Jakob
Written/Paper Submissions
will do its best to accommodate requests Disease and Variant Creutzfeldt-Jakob
to make public comment. Following the Disease by Blood and Blood Products; Submit written/paper submissions as
close of registration, FDA will Guidance for Industry.’’ The guidance follows:
determine the amount of time allotted to document provides blood collecting • Mail/Hand delivery/Courier (for
each presenter and the approximate establishments and manufacturers of written/paper submissions): Division of
time each oral presentation is to begin, plasma derivatives with comprehensive Dockets Management (HFA–305), Food
and will select and notify participants recommendations intended to minimize and Drug Administration, 5630 Fishers
by February 24, 2016. All requests to the possible risk of transmission of Lane, Rm. 1061, Rockville, MD 20852.
make oral presentations must be Creutzfeldt-Jakob Disease (CJD) and • For written/paper comments
received by the close of registration on Variant Creutzfeldt-Jakob Disease (vCJD) submitted to the Division of Dockets
Management, FDA will post your
February 24, 2016, at 4 p.m. If selected from blood and blood products. The
comment, as well as any attachments,
for presentation, any presentation guidance amends the guidance
except for information submitted,
materials must be emailed to Cara document entitled ‘‘Guidance for
marked and identified, as confidential,
Tenenbaum (see FURTHER INFORMATION Industry: Revised Preventive Measures
if submitted as detailed in
CONTACT) no later than February 26, to Reduce the Possible Risk of
‘‘Instructions.’’
2016. No commercial promotional Transmission of Creutzfeldt-Jakob Instructions: All submissions received
material will be permitted to be Disease (CJD) and Variant Creutzfeldt- must include the Docket No. FDA–
presented or distributed at the public Jakob Disease (vCJD) by Blood and 2012–D–0307 for Revised Preventive
workshop. Blood Products’’ dated May 2010 (2010 Measures to Reduce the Possible Risk of
Transcripts: Please be advised that as guidance) by finalizing and Transmission of Creutzfeldt-Jakob
soon as a transcript is available, it will incorporating the recommendations Disease and Variant Creutzfeldt-Jakob
be accessible at http://www. from the draft document entitled ‘‘Draft Disease by Blood and Blood Products;
regulations.gov. It may be viewed at the Guidance for Industry: Amendment to Guidance for Industry. Received
Division of Dockets Management (see ’Guidance for Industry: Revised comments will be placed in the docket
ADDRESSES). A transcript will also be Preventive Measures to Reduce the and, except for those submitted as
available in either hardcopy or on CD– Possible Risk of Transmission of ‘‘Confidential Submissions,’’ publicly
ROM, after submission of a Freedom of Creutzfeldt-Jakob Disease and Variant viewable at http://www.regulations.gov
Information request. The Freedom of Creutzfeldt-Jakob Disease by Blood and or at the Division of Dockets
Information office address is available Blood Products’’’ dated June 2012 (2012 Management between 9 a.m. and 4 p.m.,
on the Agency’s Web site at http:// draft guidance). Monday through Friday.
www.fda.gov. A link to the transcripts DATES: Submit either electronic or • Confidential Submissions—To
will also be available approximately 45 written comments on Agency guidances submit a comment with confidential
days after the public workshop on the at any time. information that you do not wish to be
Internet at http://www.fda.gov/Medical ADDRESSES: You may submit comments made publicly available, submit your
Devices/NewsEvents/Workshops as follows: comments only as a written/paper
Conferences/default.htm. (Select this submission. You should submit two
public workshop from the posted events Electronic Submissions copies total. One copy will include the
list.) Submit electronic comments in the information you claim to be confidential
Dated: January 7, 2016. following way: with a heading or cover note that states
Leslie Kux, • Federal eRulemaking Portal: http:// ‘‘THIS DOCUMENT CONTAINS
Associate Commissioner for Policy. www.regulations.gov. Follow the CONFIDENTIAL INFORMATION’’. The
[FR Doc. 2016–00540 Filed 1–13–16; 8:45 am]
instructions for submitting comments. Agency will review this copy, including
Comments submitted electronically, the claimed confidential information, in
BILLING CODE 4164–01–P
including attachments, to http:// its consideration of comments. The
www.regulations.gov will be posted to second copy, which will have the
DEPARTMENT OF HEALTH AND the docket unchanged. Because your claimed confidential information
HUMAN SERVICES comment will be made public, you are redacted/blacked out, will be available
solely responsible for ensuring that your for public viewing and posted on
Food and Drug Administration comment does not include any http://www.regulations.gov. Submit
confidential information that you or a both copies to the Division of Dockets
[Docket No. FDA–2012–D–0307] third party may not wish to be posted, Management. If you do not wish your
such as medical information, your or name and contact information to be
Revised Preventive Measures To
anyone else’s Social Security number, or made publicly available, you can
Reduce the Possible Risk of
confidential business information, such provide this information on the cover
Transmission of Creutzfeldt-Jakob
as a manufacturing process. Please note sheet and not in the body of your
Disease and Variant Creutzfeldt-Jakob
that if you include your name, contact comments and you must identify this
Disease by Blood and Blood Products;
mstockstill on DSK4VPTVN1PROD with NOTICES
information, or other information that information as ‘‘confidential.’’ Any
Guidance for Industry; Availability
identifies you in the body of your information marked as ‘‘confidential’’
AGENCY: Food and Drug Administration, comments, that information will be will not be disclosed except in
HHS. posted on http://www.regulations.gov. accordance with 21 CFR 10.20 and other
ACTION: Notice of availability. • If you want to submit a comment applicable disclosure law. For more
with confidential information that you information about FDA’s posting of
SUMMARY: The Food and Drug do not wish to be made available to the comments to public dockets, see 80 FR
Administration (FDA or Agency) is public, submit the comment as a 56469, September 18, 2015, or access
VerDate Sep<11>2014 16:39 Jan 13, 2016 Jkt 238001 PO 00000 Frm 00021 Fmt 4703 Sfmt 4703 E:\FR\FM\14JAN1.SGM 14JAN1](https://thefederalregister.org/doc/81_FR_1964/page/3.svg)
Document Created: 2016-01-14 02:50:52
Document Modified: 2016-01-14 02:50:52
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice of public workshop; request for comments. | |
| Dates | The public workshop will be held on March 2, 2016, from 8 a.m. to 4 p.m. Submit either electronic or written comments on the public workshop by March 31, 2016. | |
| Contact | Cara Tenenbaum, Center for Devices and Radiological Health, Food and Drug Administration, Bldg. 66, Rm. 5563, 10903 New Hampshire Ave., Silver Spring, MD 20993, 301-796-8456, [email protected] | |
| FR Citation | 81 FR 1955 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR